Cargando…

Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study)

Safety and efficacy of combination therapy of pitavastatin and fenofibrate were examined in consecutive case series with fasting serum triglycerides ≥ 150 mg/dL despite receiving pitavastatin 1 or 2 mg daily for over 2 months and additionally administered micronized fenofibrate 67 mg daily for anoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakida, Yasushi, Suzuki, Satoshi, Nomura, Hirohiko, Isomura, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699489/
https://www.ncbi.nlm.nih.gov/pubmed/23885192
http://dx.doi.org/10.4137/JCM.S7863
_version_ 1782275395238756352
author Wakida, Yasushi
Suzuki, Satoshi
Nomura, Hirohiko
Isomura, Tatsuya
author_facet Wakida, Yasushi
Suzuki, Satoshi
Nomura, Hirohiko
Isomura, Tatsuya
author_sort Wakida, Yasushi
collection PubMed
description Safety and efficacy of combination therapy of pitavastatin and fenofibrate were examined in consecutive case series with fasting serum triglycerides ≥ 150 mg/dL despite receiving pitavastatin 1 or 2 mg daily for over 2 months and additionally administered micronized fenofibrate 67 mg daily for another 4 to 16 weeks. Such low doses were selected in consideration of safety, and normal liver and renal functions were incorporated in inclusion criteria. In result, a total of 56 cases were examined. The addition of fenofibrate 67 mg to pitavastatin 1 mg/2 mg yielded a 36.8%/35.6% reduction in triglycerides and 6.4%/12.4% elevation in high-density lipoprotein cholesterol, respectively. Almost 70% of the patients achieved triglycerides <150 mg/dL. Statistically significant elevation and decrease were observed in high-density lipoprotein cholesterol level and low-density lipoprotein cholesterol, respectively. Laboratory tests for liver, renal and muscle function statistically significantly elevated after starting fenofibrate co-administration, which were considered comparable to the effect of fenofibrate alone. No myopathy or serious adverse events were reported. In conclusion, while the safety and tolerability need to be further examined over the longer term, and careful monitoring is still needed, this regimen could be considered as one of the treatment option for hypercholesterolemia associated with hypertriglyceridemia.
format Online
Article
Text
id pubmed-3699489
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-36994892013-07-24 Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study) Wakida, Yasushi Suzuki, Satoshi Nomura, Hirohiko Isomura, Tatsuya Jpn Clin Med Original Research Safety and efficacy of combination therapy of pitavastatin and fenofibrate were examined in consecutive case series with fasting serum triglycerides ≥ 150 mg/dL despite receiving pitavastatin 1 or 2 mg daily for over 2 months and additionally administered micronized fenofibrate 67 mg daily for another 4 to 16 weeks. Such low doses were selected in consideration of safety, and normal liver and renal functions were incorporated in inclusion criteria. In result, a total of 56 cases were examined. The addition of fenofibrate 67 mg to pitavastatin 1 mg/2 mg yielded a 36.8%/35.6% reduction in triglycerides and 6.4%/12.4% elevation in high-density lipoprotein cholesterol, respectively. Almost 70% of the patients achieved triglycerides <150 mg/dL. Statistically significant elevation and decrease were observed in high-density lipoprotein cholesterol level and low-density lipoprotein cholesterol, respectively. Laboratory tests for liver, renal and muscle function statistically significantly elevated after starting fenofibrate co-administration, which were considered comparable to the effect of fenofibrate alone. No myopathy or serious adverse events were reported. In conclusion, while the safety and tolerability need to be further examined over the longer term, and careful monitoring is still needed, this regimen could be considered as one of the treatment option for hypercholesterolemia associated with hypertriglyceridemia. Libertas Academica 2011-09-19 /pmc/articles/PMC3699489/ /pubmed/23885192 http://dx.doi.org/10.4137/JCM.S7863 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Original Research
Wakida, Yasushi
Suzuki, Satoshi
Nomura, Hirohiko
Isomura, Tatsuya
Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study)
title Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study)
title_full Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study)
title_fullStr Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study)
title_full_unstemmed Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study)
title_short Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study)
title_sort additional treatment with fenofibrate for patients treated with pitavastatin under ordinary medical practice for hypertriglyceridemia in japan (approach-j study)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699489/
https://www.ncbi.nlm.nih.gov/pubmed/23885192
http://dx.doi.org/10.4137/JCM.S7863
work_keys_str_mv AT wakidayasushi additionaltreatmentwithfenofibrateforpatientstreatedwithpitavastatinunderordinarymedicalpracticeforhypertriglyceridemiainjapanapproachjstudy
AT suzukisatoshi additionaltreatmentwithfenofibrateforpatientstreatedwithpitavastatinunderordinarymedicalpracticeforhypertriglyceridemiainjapanapproachjstudy
AT nomurahirohiko additionaltreatmentwithfenofibrateforpatientstreatedwithpitavastatinunderordinarymedicalpracticeforhypertriglyceridemiainjapanapproachjstudy
AT isomuratatsuya additionaltreatmentwithfenofibrateforpatientstreatedwithpitavastatinunderordinarymedicalpracticeforhypertriglyceridemiainjapanapproachjstudy